fda glp-1 safety alert october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Drug Recalls and Warnings:

Those who switched to placebo experienced rapid weight regain, with most returning to baseline weight within 12-16 weeks

[118] 5-HT: serotonin, A 2A R: adenosine A 2A receptor, cAMP: cyclic adenosine monophosphate, D 2 R: dopamine receptor D 2 , L-DOPA: levodopa, LTP: long-term potentiation, mGluR5: metabotropic glutamate receptor 5 receptor, PD: Parkinsons disease, PKA: protein kinase A

Objective - optimize for the post-game baseline: We did not treat the Super Bowl ad as a standalone bet

Eight weeks of exposure to WD at middle-age increased brain cytokines in a sex-dependent manner, in which females demonstrated increased inflammation in the amygdala in response to WD, whereas males trended towards increased levels in the ventral hippocampus

Latif W, Lambrinos KJ, Patel P, Rodriguez R